Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
Open Access
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (5) , 577-584
- https://doi.org/10.1023/a:1026406920321
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.Journal of Clinical Oncology, 1998
- Activity of Oral and Intravenous 9-Aminocamptothecin in SCID Mice Engrafted with Human LeukemiaLeukemia & Lymphoma, 1998
- Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.Journal of Clinical Oncology, 1997
- 9-Aminocamptothecin and Beyond.Annals of the New York Academy of Sciences, 1996
- Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 1996
- Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.Journal of Clinical Oncology, 1996
- Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989
- DNA topoisomerase-targeting antitumor drugs can be studied in yeast.Proceedings of the National Academy of Sciences, 1988
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979